派立明与贝特舒联合应用对降眼压的临床观察

目的评价1.00%派立明(AZOPT)与0.25%贝特舒点眼液每日两次点眼对原发性开角型青光眼、高眼压症及抗青光眼术后高眼压的降眼压效果及安全性。方法31例患者51只眼纳入为期2个月的前瞻性研究。在停用其他抗青光眼药物足够长的时间后测量基础值,用药后每2周复查一次共4次,同时观察眼局部及全身副作用。结果用药前眼压为23.85±1.80 mmHg,4次随访眼压下降均值6.55 mmHg(6.06～7.04),眼压下降率27.50%(26.62～28.59%)。少数病例出现烧灼感、视物模糊、口苦等症状,均为轻度能耐受,对视力、眼底无影响。结论派立明与贝特舒联合用药具有稳定的降眼压效果,具良好耐受性。

Efficacy of Brinzolamide combined with Betoptic in glaucoma and hypertension

Objective: To evaluate the efficacy and safety of 1.00% Brinzolamide (Azopt) combined with 0.25% Betoptic administered twice daily for 2-month in patients with primary open angle glaucoma (POAG) or ocular hypertension. Method: A total of 31 patients (51 eyes) participated in this study. Subjects were examined at baseline and every two weeks after treatment. Results: Subjects had a mean reduction in IOP of 6.55 mmHg. Azopt and Betoptic reduced intraocular pressure significantly at all time points. Our study indicates that Azopt and Betoptic provide a sustained long-term ocular hypotensive effect and tolerated causing only nonserious adverse effects that were generally local, transient and mild in severity. Conclusions: Azopt and Betoptic demonstrated IOP-lowering efficacy and are well tolerated.